X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs SUN PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD SUN PHARMA ALEMBIC LTD/
SUN PHARMA
 
P/E (TTM) x 51.7 25.8 200.3% View Chart
P/BV x 2.1 2.7 77.3% View Chart
Dividend Yield % 0.5 0.5 104.5%  

Financials

 ALEMBIC LTD   SUN PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
SUN PHARMA
Mar-18
ALEMBIC LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs72701 10.3%   
Low Rs34433 7.8%   
Sales per share (Unadj.) Rs4.7110.4 4.3%  
Earnings per share (Unadj.) Rs6.111.0 55.6%  
Cash flow per share (Unadj.) Rs6.217.2 36.2%  
Dividends per share (Unadj.) Rs0.202.00 10.0%  
Dividend yield (eoy) %0.40.4 107.1%  
Book value per share (Unadj.) Rs40.7158.8 25.6%  
Shares outstanding (eoy) m267.032,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.35.1 219.4%   
Avg P/E ratio x8.751.6 16.8%  
P/CF ratio (eoy) x8.532.9 25.8%  
Price / Book Value ratio x1.33.6 36.5%  
Dividend payout %3.318.2 18.0%   
Avg Mkt Cap Rs m14,1391,360,021 1.0%   
No. of employees `000NA17.8 0.0%   
Total wages/salary Rs m20753,671 0.4%   
Avg. sales/employee Rs ThNM14,890.9-  
Avg. wages/employee Rs ThNM3,017.1-  
Avg. net profit/employee Rs ThNM1,480.6-  
INCOME DATA
Net Sales Rs m1,255264,895 0.5%  
Other income Rs m3708,388 4.4%   
Total revenues Rs m1,625273,282 0.6%   
Gross profit Rs m11156,081 0.2%  
Depreciation Rs m3814,998 0.3%   
Interest Rs m25,176 0.0%   
Profit before tax Rs m44244,295 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m248,452 0.3%   
Profit after tax Rs m1,63026,338 6.2%  
Gross profit margin %8.921.2 41.8%  
Effective tax rate %5.419.1 28.4%   
Net profit margin %129.89.9 1,306.0%  
BALANCE SHEET DATA
Current assets Rs m1,867316,359 0.6%   
Current liabilities Rs m591198,643 0.3%   
Net working cap to sales %101.644.4 228.7%  
Current ratio x3.21.6 198.3%  
Inventory Days Days9495 99.4%  
Debtors Days Days74108 68.3%  
Net fixed assets Rs m1,791213,178 0.8%   
Share capital Rs m5342,399 22.3%   
"Free" reserves Rs m10,324378,606 2.7%   
Net worth Rs m10,858381,006 2.8%   
Long term debt Rs m4117,721 0.2%   
Total assets Rs m11,591643,028 1.8%  
Interest coverage x260.99.6 2,729.4%   
Debt to equity ratio x00 8.2%  
Sales to assets ratio x0.10.4 26.3%   
Return on assets %14.14.9 287.2%  
Return on equity %15.06.9 217.2%  
Return on capital %15.210.0 151.5%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1940,816 0.0%   
Fx outflow Rs m26430,143 0.9%   
Net fx Rs m-24410,673 -2.3%   
CASH FLOW
From Operations Rs m23639,072 0.6%  
From Investments Rs m-224-33,708 0.7%  
From Financial Activity Rs m-27-15,393 0.2%  
Net Cashflow Rs m-15-7,359 0.2%  

Share Holding

Indian Promoters % 64.0 63.7 100.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.1 3.9%  
FIIs % 9.7 23.0 42.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 8.3 314.5%  
Shareholders   54,701 133,026 41.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare ALEMBIC LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Feb 22, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - IPCA LABS COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS